Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $8
Bausch Health, Salix Announce Data on Xifaxan After OHE Hospitalization
Bausch Health Up 3.5% In US Premarket As Says New Analysis Suggests Efficacy of Xifaxan
Xifaxan(R) (Rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated With Reduced Risk of 30-Day OHE Rehospitalization
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Cuts Target Price to $8
Xifaxan (Rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated With Reduced Risk of 30-Day OHE Rehospitalization
Expand
73164454 : Staying away from China Stocks is not an issue with any company, but rather due to uncertainty.
105742796 Learner : Stock volatility
New plans new forecast
Revenue release
SPICYDOC辣刀客 73164454 : IS there any certainty with any stocks unless insider information? Two things certain about Chinese stocks are low valuation, and determination to bottom up with government support.
Laine Ford : I say no more talk to yall now